<DOC>
	<DOCNO>NCT02143765</DOCNO>
	<brief_summary>Mitiglinide , benzylsuccinic acid derivative , exert selective action ATP-dependent K ( KATP ) channel pancreatic Î²-cells reportedly possess strong affinity channel compare insulinotropic sulphonylurea receptor ligands , namely repaglinide nateglinide . Preprandial administration mitiglinide efficiently reduce postprandial hyperglycemia improve overall glycemic control . This 12-week , open , randomize study compare Mitiglinide versus Acarbose . The purpose study evaluate efficacy safety Mitiglinide v Acarbose patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety Mitiglinide v Acarbose Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Group I ( Mitiglinide ) : Mitiglinide 10 mg three time day , orally , 12 week Group II ( Acarbose ) : Acarbose 50 mg three time day , orally , 12 week Total subject : 248 , randomize 2 group ratio 1:1 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<criteria>1 . Subjects age 18 70 , regardless gender 2 . Subjects type2 diabetes mellitus diagnose accord 1999 WHO criteria within 5 year 3 . Subjects receive insulin secretagogues , insulin sensitizer , incretin mimetics alphaglucosidase inhibitor 4 . Subjects whose fast blood glucose [ FBG ] between7.0 and10.0 mmol/L HbA1c ratio 7.0 % 10.0 % Note : Incretin mimetics contain glucagonlike peptide 1 ( GLP1 ) receptor agonist ( include GLP1 analogue ) dipeptidyl peptidase 4 inhibitor . 1 . Subjects abnormal hepatic function whose aspartate transaminase ( AST ) alanine transaminase ( ALT ) 2 time high upper limit normal ( ULN ) 2 . Subjects renal disfunction whose plasma creatinine concentration 1.1 ULN positive urine protein 3 . Subjects severe heart disease , liver disease , kidney disease serious organic disease 4 . Subjects chronic intestinal disease associate mark disorder digestion absorption may deteriorate result increase gas formation intestine ( like Gastrocardiac Syndrome , severe hernia , intestinal obstruction , intestinal ulcer intestinal surgery ) 5 . Subjects endocrine system diseases hyperthyroidism cushing 's syndrome etc . 6 . Subject contraindicated hypersensitivity experimental drug comparator drug 7 . Subjects participate clinical study subject within 3 month study 8 . Female subject pregnant , lactate without contraception childbearing potential 9 . Subjects judge unfit study investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Mitiglinide</keyword>
	<keyword>Acarbose</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>